Core Insights - Century Therapeutics is expanding its Phase 1 CALiPSO-1 trial of CNTY-101 to include idiopathic inflammatory myopathy and diffuse cutaneous systemic sclerosis, aiming to explore its potential in underserved autoimmune disease categories [1][3] - The Phase 1 ELiPSE-1 study of CNTY-101 in r/r B-cell lymphomas has shown an overall response rate (ORR) of 83% at Dose Level 3B, indicating a favorable safety profile [1][4] - The company ended Q3 2024 with cash and equivalents of 244.7 million, extending its cash runway into the second half of 2026 due to organizational efficiencies [1][10] Research & Development Highlights - The CALiPSO-1 trial has been amended to evaluate CNTY-101 in additional autoimmune diseases, with a basket protocol design to assess safety and preliminary efficacy [3] - Updated interim data from the ELiPSE-1 study shows increased ORR at higher doses, with no dose-limiting toxicities reported [4][5] - CNTY-101 demonstrated persistence upon repeated dosing, supporting the efficacy of Century's Allo-Evasion™ technology [5][6] Business Highlights - Following the integration of Clade Therapeutics, the company is conducting a strategic review of its preclinical pipeline, with results expected in Q1 2025 [9] - Organizational changes have been implemented to enhance efficiencies, extending the expected cash runway into the second half of 2026 [9][12] - New appointments include Morgan Conn as CFO and Chad Cowan as CSO, with Hy Levitsky transitioning to an advisory role [9] Financial Results - As of September 30, 2024, the company reported cash, cash equivalents, and marketable securities of 244.7 million, down from 261.8 million at the end of 2023 [10] - R&D expenses increased to 27.2 million for Q3 2024, primarily due to the progression of clinical trials and increased manufacturing activity [11] - The net loss for Q3 2024 was 32.7 million in Q3 2023 [11][19]
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates